Business
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Two near-term data catalysts expected in 2023\nEntered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal bipolar depression; potential for up to $330 million in milestones and double-digit royaltiesPublication of STABIL-B trial in the International Journal of Bipolar Disorders: first oral antidepressant to demonstrate reduction in suicidality with significant improvement in depression scores compared to standard of care medicationOngoing Phase 2b/3 trial of NRX-101 in suicidal bipolar depression is within 20 patients of data readout. Data expected in Q4 2023Newly released data demonstrate high levels of compliance and inter-rater reliabilityLicensed US Patent for use of D-Cycloserine (DCS) to treat chronic painAnnounced plan to develop NRX-101™ for chronic pain indications, awaiting results of 200 person DOD-funded trial in treatment of chronic pain with DCS in coming monthsFiling Investigational New Drug application with FDA to treat chronic pain with NRX-101Management to host a conference call today at 4:30 PM ETRADNOR, Pa., Aug. 14, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2023, and provided a business update.\n\"We anticipate multiple near-term data catalysts in our suicidal bipolar depression and chronic pain clinical programs. Our internal focus has been on driving our ongoing phase 2b/3 trial to a data readout, which we expect in Q4 2023. The newly-published peer-reviewed results from our phase 2 STABIL-B trial document that NRX-101 is the first oral antidepressant to demonstrate a statistically significant reduction in suicidality together with a statistically-significant reduction in depression compared to standard of care medication. Today, we have posted blinded results from our ongoing clinical trial documenting the 94% concordance in measurement of the primary endpoint (i.e. the MADRS depression scale) between our study sites and our internal master raters. Psychiatry trials often succeed or fail based on their ability to control the accuracy with which the endpoints are measured and this measure of Inter-rater reliability exceeds that report...